CD34 and hereditary disease: In our final set of experiments, we demonstrated for the first time the gene editing of mobilized PB CD34+ cells directly obtained from FA‐A patients, the target population currently considered for the gene therapy of several inherited diseases, including FA (see review in Tolar et al, 2012).